Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Phase III For CF Combo Shows Power Of “Breakthrough” Designation

This article was originally published in The Pink Sheet Daily

Executive Summary

Pivotal trials for the combination of Kalydeco and VX-809 will measure safety and efficacy over 24 weeks, whereas Kalydeco monotherapy gained FDA approval on the basis of 56 weeks of data; Vertex and FDA developed the protocol together following a recent “breakthrough therapy” designation for the two-drug combo.

Advertisement

Related Content

Vertex’s Orkambi Efficacy Data May Make FDA More Cautious With Other ‘Breakthroughs’
Vertex’s Combo Drug Orkambi Faces FDA Doubts About Lumacaftor’s Benefit
Return Of Vertex’s Ivacaftor To FDA Panel May Signal Efficacy Concerns
Vertex CF Combo Succeeds In Phase III, But Secondary Endpoints May Be Crucial
Vertex CF Combo Succeeds In Phase III, But Secondary Endpoints May Be Crucial
Fourth Quarter Earnings Calls, In Brief
FDA’s First Breakthrough Designations Continue Vertex Kalydeco’s Regulatory Successes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel